Statin therapy in lupus-mediated atherogenesis: two birds with one stone?
| Autor: | Sander I. van Leuven, Erik S.G. Stroes, Paul P. Tak, Yanice V. Mendez-Fernandez, Amy S. Major |
|---|---|
| Přispěvatelé: | Clinical Immunology and Rheumatology, Amsterdam Cardiovascular Sciences, Vascular Medicine, Amsterdam institute for Infection and Immunity |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Immunology Article General Biochemistry Genetics and Molecular Biology Mice Rheumatology In vivo immune system diseases Internal medicine medicine Animals Humans Lupus Erythematosus Systemic Immunology and Allergy In patient skin and connective tissue diseases ATHEROSCLEROTIC VASCULAR DISEASE Systemic lupus erythematosus Lupus erythematosus business.industry Vascular disease Atherosclerosis medicine.disease Disease Models Animal Statin therapy Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Annals of the rheumatic diseases, 70(2), 245-248. BMJ Publishing Group |
| ISSN: | 0003-4967 |
| DOI: | 10.1136/ard.2010.133827 |
| Popis: | The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|